Type 1 and 3 von Willebrand disease (VWD) represent the most frequent and rarest forms, respectively of the most common inherited bleeding disorder described in humans. Both conditions are quantitative traits with reductions of von Willebrand factor (VWF) being mild/moderate in type 1 VWD and severe in type 3 disease. In this research proposal, we will further pursue the pathogenesis of these conditions.
In Aim #1 of the project we will carry out studies to further examine the role of sequence variation in and around the VWF gene in the pathogenesis of type 1 and 3 VWD. These studies will determine the potential pathogenetic role of regulatory region variants, intronic variants and copy number variation.
Aim #2 of the project will involve a re-assessment of the association data presented in the recently published CHARGE genome-wide association study meta-analysis. These studies will be performed primarily to fine-map the original SNP associations described in the CHARGE meta-analysis.
Aims 3 and 4 will involve studies to address the finding of five novel pathogenetic candidates reported in the CHARGE GWAS report.
In Aim #3 we will perform studies to evaluate the role of two candidates identified in CHARGE that appear to have the potential to play a role in VWF biosynthesis, storage and/or secretion. These studies will involve a combination of cell biology and genetic approaches to determining the role of Syntaxin Binding Protein 5 (STXBP5) and Syntaxin 2 (STX2) in regulating VWF synthesis and release from cells. In parallel with the studies to evaluate normal STXBP5 and STX2 function, we will search for variants of these proteins in our type 1 and 3 VWD populations and will determine the influence of selected variants in the experimental systems that we have established. Finally, in Aim #4 we will use a similar combination of biology and genetics to investigate the influence of accelerated clearance of VWF by the receptors C-type lectin domain family 4 member M, Stabilin-2 and Scavenger receptor class A member 5. Again, after characterizing the role of the normal receptors in binding to and clearing VWF, we will evaluate the influence of variant forms of the receptors derived from a genetic search of our type 1 VWD patient cohorts.

Public Health Relevance

This research project addresses the genetic background of two inherited bleeding disorders, one, type 1 von Willebrand disease, that is the most common bleeding problem encountered in the general population, and the second, type 3 von Willebrand disease, a rare variant form of the condition. Both diseases result in chronic morbidities due to recurrent excessive mucocutaneous bleeding.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL081588-07
Application #
8424984
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
7
Fiscal Year
2013
Total Cost
$346,476
Indirect Cost
$6,753
Name
Medical College of Wisconsin
Department
Type
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Obser, T; Ledford-Kraemer, M; Oyen, F et al. (2016) Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami. J Thromb Haemost 14:1725-35
Hawke, Lindsey; Bowman, Mackenzie L; Poon, Man-Chiu et al. (2016) Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism. Blood 128:584-93
Ozel, A B; McGee, B; Siemieniak, D et al. (2016) Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance. J Thromb Haemost 14:1888-98
Flood, Veronica H; Christopherson, Pamela A; Gill, Joan Cox et al. (2016) Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood 127:2481-8
Baumgartner, C K; Mattson, J G; Weiler, H et al. (2016) Targeting Factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. J Thromb Haemost :
Haberichter, Sandra L (2015) von Willebrand factor propeptide: biology and clinical utility. Blood 126:1753-61
Chen, Junmei; Hinckley, Jesse D; Haberichter, Sandra et al. (2015) Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. Blood 126:262-9
Goodeve, A C (2015) Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost 13:1184-95
Avila, M L; Lee, K-J; Bouskill, V et al. (2015) Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition. Haemophilia 21:e89-92
Deforest, M; Grabell, J; Albert, S et al. (2015) Generation and optimization of the self-administered bleeding assessment tool and its validation as a screening test for von Willebrand disease. Haemophilia 21:e384-8

Showing the most recent 10 out of 97 publications